| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Sialic acid synthases and sialyltransferases; cell surface receptors involved in immune recognition. 9-Amino-NeuAc is a substrate for sialic acid synthases and can be converted to CMP-9-amino-NeuAc, the activated form required for incorporation into glycoconjugates by sialyltransferases. Once incorporated into cell surface glycoproteins and glycolipids, the modified sialic acid can modulate cell surface immunogenicity. Sialic acids play critical roles in cellular recognition and signaling processes. The mechanism of action involves interaction with specific receptors on cell surfaces. The compound's amino group allows for conjugation with other molecules, enabling targeted delivery and functional studies.
|
|---|---|
| ln Vitro |
9-Amino-NeuAc is a substrate for sialic acid synthases and can be converted to CMP-9-amino-NeuAc, the activated form required for incorporation into glycoconjugates. The compound can be used to target liposome synthesis while modulating tumor surface immunogenicity. The amino group at the 9-position makes it a functionalized version of sialic acid, allowing for easier conjugation with other molecules, such as proteins or nanoparticles. The compound's ability to be incorporated into cell surface glycans enables studies of sialic acid function in cellular recognition and signaling.
|
| ln Vivo |
In vivo studies of 9-amino-NeuAc are limited. The compound can be used to target liposome synthesis while modulating tumor surface immunogenicity. By incorporating the modified sialic acid into cell surface glycoconjugates, the compound may alter immune recognition of tumor cells. Sialic acids play critical roles in cellular recognition and signaling processes, and modifications to sialic acid structure can affect these functions. Further in vivo studies are needed to fully characterize the compound's pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Non-cell-based assays for 9-amino-NeuAc include enzymatic assays to assess its substrate activity for sialic acid synthases and sialyltransferases. The conversion of 9-amino-NeuAc to CMP-9-amino-NeuAc can be measured using HPLC or radiometric assays. Binding to sialic acid-binding proteins such as siglecs can be assessed using surface plasmon resonance (SPR) or ELISA. For compound characterization, standard analytical methods including HPLC, NMR, and mass spectrometry are used to confirm identity and purity.
|
| Cell Assay |
Cell-based assays for 9-amino-NeuAc use various cell lines to study its incorporation into cell surface glycoconjugates and its effects on cell function. Cells are cultured with 9-amino-NeuAc, and incorporation into glycoproteins and glycolipids is assessed using lectin binding, antibody detection, or metabolic labeling with fluorescent or radioactive probes. Effects on cell surface immunogenicity are assessed by measuring immune cell activation or binding of sialic acid-binding proteins. The compound's effects on tumor cell recognition by immune cells can be studied in co-culture assays.
|
| Animal Protocol |
In vivo studies of 9-amino-NeuAc are limited. Potential applications include: tumor models for studying modulation of tumor surface immunogenicity; and models for studying sialic acid function in development and disease. The compound can be administered via various routes, and incorporation into tissue glycoconjugates can be assessed by mass spectrometry or lectin histochemistry. Further studies are needed to establish the compound's in vivo efficacy and safety.
|
| ADME/Pharmacokinetics |
9-Amino-NeuAc has a molecular formula of C₁₁H₂₀N₂O₈ and a molecular weight of 308.29 g/mol. It is soluble in DMSO at 50 mg/mL (162.18 mM) with ultrasonic assistance. The compound should be stored at -20°C. It has a purity of ≥98%. The compound is a sialic acid derivative and is intended for research use only. It is not for human consumption. Specific storage and handling conditions should be followed as per the manufacturer's recommendations.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 9-amino-NeuAc are limited. As a sialic acid derivative, it is expected to have low toxicity. Sialic acids are naturally occurring carbohydrates found in all mammalian cells. The compound is intended for research use only. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment.
|
| References |
|
| Additional Infomation |
9-Amino-NeuAc (9-Amino-N-acetylneuraminic acid) is a C-9 modified derivative of N-acetylneuraminic acid (Neu5Ac), the primary sialic acid in mammals. Sialic acids are nine-carbon sugars that play critical roles in cellular recognition, signaling, and immune modulation. The amino group at the 9-position allows for conjugation with other molecules, enabling targeted delivery and functional studies. 9-Amino-NeuAc is a substrate for sialic acid synthases and can be incorporated into glycoconjugates via the sialic acid biosynthetic pathway. The compound can be used to target liposome synthesis while modulating tumor surface immunogenicity, making it of interest for cancer immunotherapy research. It is for research use only.
|
| Exact Mass |
308.122
|
|---|---|
| CAS # |
153232-60-1
|
| PubChem CID |
124397065
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
406
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1[C@@H]([C@@H](CN)O)O)(C(=O)O)O)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
